FDA accepts Sandoz application for biosimilar filgrastim
24 July 2014 | By Novartis
Sandoz announced that the US Food and Drug Administration has accepted its Biologics License Application for filgrastim...
List view / Grid view
News
PLEGRIDY™ (Peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis
24 July 2014 | By Biogen Idec
Biogen Idec announced that the European Commission has granted marketing authorization for PLEGRIDYTM (peginterferon beta-1a)...
Merck initiates Phase 3 study of Letermovir, an investigational antiviral for prevention of cytomegalovirus (CMV) infection in high-risk bone marrow transplant patients
24 July 2014 | By Merck
Merck announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228)...
Heart patients in England and Wales offered more choice of therapies as NICE extends recommendations for prasugrel
24 July 2014 | By Eli Lilly and Company & Daiichi Sankyo
Revised guidance from the National Institute for Health and Care Excellence, recommends once-daily, oral antiplatelet prasugrel (Efient®)...
Sucampo announces publication of NICE recommendation for AMITIZA® (Lubiprostone)
23 July 2014 | By Sucampo Pharmaceuticals, Inc
Sucampo Pharmaceuticals, Inc. announced that the United Kingdom’s National Institute of Health and Care Excellence has published the technology appraisal guidance recommending the use of AMITIZA® (lubiprostone)...
MedImmune and Advaxis partner on immuno-oncology combination clinical trial
22 July 2014 | By AstraZeneca
AstraZeneca announced that MedImmune has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies...
ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir
22 July 2014 | By GlaxoSmithKline
...with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1.
Boehringer Ingelheim establishes a research alliance with the University of Toronto, the Toronto-based University Health Network and the Mount Sinai Hospital
22 July 2014 | By Boehringer Ingelheim
...to investigate new therapeutic concepts in the field of ubiquitin signalling biology.
GE introduces new Sievers M9 Total Organic Carbon Analyzer for ultrapure and process waters
GE has announced the release of its new Sievers M9 Total Organic Carbon (TOC) Analyzer, which has been designed to measure TOC in a broad range of samples from ultrapure water to process waters. The new M9 Analyzer enhances productivity by producing TOC results in two minutes, twice as fast…
Teva completes acquisition of Labrys
21 July 2014 | By Teva
...opens door to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.
Thermo Fisher Scientific transforms chromatography by reimagining UHPLC
Thermo Fisher Scientific, the world leader in serving science, today unveiled a new high performance liquid chromatography system designed from the ground up to provide new levels of performance, productivity and usability when used as a standalone system or with the latest mass spectrometers
AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK
18 July 2014 | By AstraZeneca
AstraZeneca revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK...
Amgen announces positive Phase 3 results for AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis
18 July 2014 | By Amgen
Amgen announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease...
Trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination demonstrated overall survival benefit compared to vemurafenib
18 July 2014 | By GlaxoSmithKline
...phase III BRAF V600-mutant metastatic melanoma study stopped early.
Bristol-Myers Squibb and Pfizer announce enrollment of first patient in Phase IV EMANATE trial to assess effectiveness and safety of Eliquis® (apixaban) in patients with NVAF undergoing cardioversion
18 July 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation undergoing cardioversion...
